News Archive

May 2019

• Key Release May 24, 2019

  AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

  SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1],[2…
• 
  Story May 24, 2019 Discovery

  Cancer research drives breast cancer treatment forward

  Novartis team perseveres to develop more personalized approach to breast cancer therapy.

• Press Release May 23, 2019

  Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

  Driving growth through cutting edge pipeline with 15 in-market blockbusters and more than 25 potential blockbusters in development, including 10+ planned launches by 2021  Strong progress on…
• Press Release May 22, 2019

  Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment

  New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled…
• 
  Story May 17, 2019 Discovery

  Respiratory clinical trials: Putting patients at the heart of research

  All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.

• Press Release May 16, 2019

  Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

  Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO   Primary…
• Featured News May 15, 2019

  SOLAR-1 NEJM Publication

• Press Release May 10, 2019

  Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS

  Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya® (fingolimod) 0.5mg had significantly fewer relapses than patients…
• 
  Story May 09, 2019 Discovery

  Women in Science: Sandrine Piret-Gérard

  Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.

• Press Release May 09, 2019

  Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

  Sandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China's…
• Key Release May 09, 2019

  Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

  Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline…
• Press Release May 08, 2019

  Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS

  Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive…